Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

Patient-Reported Outcomes in Patients Receiving Niraparib in the PRIMA/ENGOT-OV26/GOG-3012 Trial

Conference Correspondent  - ESMO 2020

The PRIMA study was a phase 3, double-blind, placebo-controlled study designed to evaluate the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib for patients with newly diagnosed advanced ovarian, primary peritoneal, or fallopian tube cancer with a complete or partial response to first-line platinum-based chemotherapy. In this study, patients received niraparib or placebo once daily for 36 months or until disease progression. Although the primary end point of the study was progression-free survival, this analysis reports on patient-reported outcomes (PROs), a secondary end point of the trial, with relevant data having been collected every 8 weeks for 56 weeks, and then every 12 weeks thereafter until treatment was no longer ongoing. If patients discontinued treatment, PRO evaluations were completed at discontinuation and at 4, 8, 12, and 24 weeks. PRO instruments included FOSI, EQ-5D-5L, EORTC-QLQ-C30, and EORTC-QLQ-OV28.

All PRO evaluations were completed with a high rate of compliance (>80%) during the study. The EORTC-QLQ-C30 outcomes indicated that there is no difference in health-related quality-of-life outcomes or physical function between those treated with niraparib and those treated with placebo. At each time point, mean scores for the FOSI-assessed symptoms of lack of energy, nausea, vomiting, and stomach cramps were similar for those treated with niraparib and those treated with placebo. Mean FOSI health utility index scores were similar between treatment arms throughout the treatment period. There were no reported differences between treatments for fatigue or pain. The ovarian-specific EORTC-QLQ-OV28 showed no difference in abdominal/gastrointestinal symptoms or other chemotherapy-related side-effect scores. In addition, the EQ-5D-5L showed no significant difference in health utility index–assessed change from baseline between the 2 study arms, nor was there a difference in the scores obtained with visual analog scale.

These results are consistent with previously reported PRO results and indicate that receiving niraparib in the PRIMA study was not associated with a decrease in quality of life compared with placebo.

Reference

Abstract and Mini-Oral Presentation 810MO. ESMO 2020. September 19-21, 2020. Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial.

Related Items
Olaparib Significantly Improves Survival in Men with Metastatic Prostate Cancer and BRCA Mutations
Patricia Stewart
TOP - November 2020 Vol 13, No 6 published on November 9, 2020 in ESMO 2020
“Practice-Changing” Results Seen with Adjuvant Abemaciclib plus Endocrine Therapy in HR-Positive, HER2-Negative Breast Cancer
Patricia Stewart
TOP - November 2020 Vol 13, No 6 published on November 9, 2020 in ESMO 2020
Cabozantinib plus Nivolumab Offers New First-Line Treatment Option for Patients with Advanced Renal-Cell Carcinoma
Patricia Stewart
TOP - November 2020 Vol 13, No 6 published on November 9, 2020 in ESMO 2020
Adjuvant Abemaciclib plus Endocrine Therapy Game-Changer in High-Risk, HR-Positive, HER2-Negative Early Breast Cancer
Phoebe Starr
Web Exclusives published on November 3, 2020 in ESMO 2020
Trabectedin/PLD versus Carboplatin/PLD in Recurrent Ovarian Cancer Progressing within 6-12 Months After Last Platinum Line
Conference Correspondent  published on September 23, 2020 in ESMO 2020
Safety and Efficacy of XMT-1536 in Ovarian Cancer: Subgroup Analysis from a Phase 1 Expansion Study
Conference Correspondent  published on September 23, 2020 in ESMO 2020
Maintenance Olaparib plus Bevacizumab for Newly Diagnosed High-Grade Ovarian Cancer: Second Progression-Free Survival
Conference Correspondent  published on September 23, 2020 in ESMO 2020
Real-World Data on Platinum Therapy in High-Grade Serous Ovarian Cancer Patients Progressing After PARP Inhibitor Treatment
Conference Correspondent  published on September 23, 2020 in ESMO 2020
Atezolizumab in Patients with Newly Diagnosed Stage III or Stage IV Ovarian Cancer
Conference Correspondent  published on September 23, 2020 in ESMO 2020
Mirvetuximab Soravtansine in Combination with Carboplatin and Bevacizumab in Recurrent Ovarian Cancer
Conference Correspondent  published on September 22, 2020 in ESMO 2020
Last modified: September 22, 2020